Home News & Media Press Releases

Recent Pfizer Press Releases

  • Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
    3/1/16 11:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Cowen and Company 36th Annual Healthcare Conference on Tuesday, March 8, 2016 at 10:40 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 36th Annual Healthcare Conferencemore...
  • Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
    2/24/16 11:15 am EST

    XELJANZ XR provides RA patients a new once-daily dosing option

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). XELJANZ XR is the first and only once-daily oral RA treatment in its class, known as Janus kinase (JAK) inhibitorsmore...
  • Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer
    2/19/16 4:35 pm EST

    First-in-class Therapy Now Approved for Use in a Broader Range of Women

    New Indication Supported by Results of Phase 3 PALOMA-3 Trial of IBRANCE in Combination with Fulvestrant

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant in women withmore...
  • WYETH REACHES AGREEMENT IN PRINCIPLE TO RESOLVE MEDICAID DRUG REBATE CLAIMS FOR 2001-2006 PERIOD FOR PROTONIX
    2/16/16 6:45 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported today that its Wyeth subsidiary has reached an agreement in principle to resolve claims alleging that Wyeth’s practices relating to the calculation of Medicaid rebates for its drug Protonix (pantoprazole sodium) between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. When finalized, the agreement in principle is expected to fully more...
  • Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications
    2/9/16 6:57 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. commends today’s recommendation by the United States (U.S.) Food and Drug Administration’s (FDA) Arthritis Advisory Committee to approve the investigational biosimilar infliximab (CT-P13) across all eligible indications by a vote of 21 to three. Celltrion's proposed biosimilar infliximab, to which Pfizer holds exclusive U.S. commercialization rights, is the first biosimilar monoclonal antibody (mAb) therapy to be reviewed by the FDAmore...
  • Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction
    2/8/16 9:30 am EST

    Pfizer will continue to manage its commercial operations through two distinct businesses – the innovative products business and the established products business – after the completion of the proposed transaction

    Pfizer continues to expect to make a decision about a potential separation of the combined company’s innovative and established businesses by no later than the end of 2018

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction. As previously announced, following the closing, Brent Saunders will become President and Chief Operating Officer of the combined company with responsibility for the oversight of Pfizer and Allergan’s combined commercial businesses, manufacturing and strategymore...
  • PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS
    2/2/16 6:45 am EST

    PROVIDES 2016 FINANCIAL GUIDANCE

    • Fourth-Quarter 2015 Reported Revenues(1) of $14.0 Billion, Reflecting 14% Operational Growth Driven by 22% Operational Growth from the Innovative Products Business
    • Full-Year 2015 Reported Revenues(1) of $48.9 Billion, Reflecting 6% Operational Growth Driven by 19% Operational Growth from the Innovative Products Business
    • Fourth-Quarter 2015 Adjusted Diluted EPS(2) of $0.53 and Reported Diluted EPS(1) of $0.10; Full-Year 2015 Adjusted Diluted EPS(2) of $2.20 and Reported Diluted EPS(1) of $1.24
    • Provides 2016 Financial Guidance
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2015 and provided 2016 financial guidance. On September 3, 2015, Pfizer acquired Hospira, Inc. (Hospira). Consequently, and in accordance with Pfizer's domestic and international reporting periods(3), full-year financial results for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospiramore...
  • Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
    2/1/16 6:55 am EST
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) today announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, includingmore...
  • Pfizer Acquires Treerly and Its Family of Products from Sirio Pharma
    1/13/16 7:04 pm EST
    SHANGHAI--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has acquired Sirio Pharma Co. Ltd.’s wholly-owned subsidiary, Treerly Health Co., Ltd., and its family of Treerly products. Treerly is one of the top healthcare brands in China’s retail channel and consists of an extensive portfolio of products uniquely designed to meet women’s nutritional healthcare needs throughout their lives. The Treerly portfolio complements Pfizer Consumer Healthcare’more...
  • ChapStick® Announces Actress Rachel Bilson as New Brand Spokesperson
    1/11/16 8:32 am EST

    Campaign Marks Brand’s Focus on Skincare for Lips

    MADISON, N.J.--(BUSINESS WIRE)--Pfizer® Consumer Healthcare, the makers of ChapStick®, America’s favorite lip balm, today announced actress Rachel Bilson as the brand’s newest spokesperson. Rachel will appear in a robust marketing campaign to elevate the importance of skincare for lips and communicate the iconic brand’s continued innovation. Rachel’s partnership with the brand will focus on the advanced skincare line featuring ChapStick® Total Hydration 100% Naturalmore...
Business Wire NewsHQ℠